Christophe

NRC Health Expands Leadership Team to Accelerate Innovation, Meet Growing Demand for Insights and Solutions

Retrieved on: 
Thursday, February 1, 2024

NRC Health, the leading provider of human-centered healthcare solutions and data-driven insights, is elevating its leadership team with the appointment of four executive-officer positions.

Key Points: 
  • NRC Health, the leading provider of human-centered healthcare solutions and data-driven insights, is elevating its leadership team with the appointment of four executive-officer positions.
  • The strategic move will allow NRC Health to accelerate innovation while continuing to provide exceptional customer experiences to its partners.
  • Christophe Louvion brings decades of executive leadership skills to his role as Chief Product and Technology Officer at NRC Health.
  • During his career, he has held consulting and leadership positions at Practicing Excellence, NRC Health, Connect, AEGON, and the Gallup Organization.

ASML Supervisory Board intends to appoint Christophe Fouquet as President and Chief Executive Officer

Retrieved on: 
Thursday, November 30, 2023

ASML’s Co-Presidents Peter Wennink and Martin van den Brink to retire on April 24, 2024

Key Points: 
  • ASML’s Co-Presidents Peter Wennink and Martin van den Brink to retire on April 24, 2024
    VELDHOVEN, the Netherlands, November 30, 2023 – The Supervisory Board of ASML Holding NV (ASML) announces that it intends to appoint Christophe Fouquet, currently ASML’s Chief Business Officer and member of the Board of Management, as the company’s next President and Chief Executive Officer.
  • On the same date, ASML’s Co-Presidents Peter Wennink and Martin van den Brink will retire from ASML upon completion of their current appointment terms.
  • Nils Andersen, Chairman of the Supervisory Board, said: “The Supervisory Board, together with the management team, has gone through a comprehensive succession planning process.
  • Christophe has been with ASML for 15 years, with a major focus on ASML technology, products and customers.

X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Thursday, November 9, 2023

BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the third quarter ended September 30, 2023 and highlighted key recent and upcoming expected milestones.

Key Points: 
  • ET
    BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the third quarter ended September 30, 2023 and highlighted key recent and upcoming expected milestones.
  • The FDA has notified X4 that it does not currently plan to hold an advisory committee meeting to review the filing.
  • Cash, Cash Equivalents, Restricted Cash, and Short-Term Marketable Securities: X4 had $142.7 million in cash, cash equivalents, restricted cash, and marketable securities as of September 30, 2023.
  • The live webcast will be accessible through the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com .

Last chance to win one of four replica championship bicycles

Retrieved on: 
Tuesday, September 19, 2023

CHICAGO, Sept. 19, 2023 /PRNewswire/ --Women's cycling is currently enjoying a remarkable surge in popularity and success, thanks in no small part to the achievements of four exceptional women. On a bicycle women can achieve amazing things, as demonstrated by the incredible careers of professional cyclists Annemiek van Vleuten, Marianne Vos, Kate Courtney, and Evie Richards.

Key Points: 
  • Each of these remarkable athletes, in collaboration with their brand sponsors, provided a replica of the bicycle they used during the Championships.
  • World Bicycle Relief is a global nonprofit organization dedicated to providing access to education, healthcare, and economic opportunities through the power of bicycles.
  • By raffling these exclusive replica championship bicycles, World Bicycle Relief aims to raise critical funds to continue its mission.
  • To enter the raffle for a chance to win one of these four replica championship bicycles, simply support World Bicycle Relief through viprize.org/wbr .

Slone Partners Places Christophe Arbet-Engels as Chief Medical Officer at X4 Pharmaceuticals

Retrieved on: 
Thursday, August 31, 2023

SOUTH RIDING, Va., Aug. 31, 2023 /PRNewswire-PRWeb/ -- Slone Partners, a nationwide executive search firm for life sciences, biotechnology, and healthcare companies, today announced the successful placement of Christophe Arbet-Engels, MD, PhD, as Chief Medical Officer (CMO) at X4 Pharmaceuticals, Inc., a biopharmaceutical company developing novel small molecule therapeutics to benefit patients with diseases of the immune system.

Key Points: 
  • SOUTH RIDING, Va., Aug. 31, 2023 /PRNewswire-PRWeb/ -- Slone Partners , a nationwide executive search firm for life sciences, biotechnology, and healthcare companies, today announced the successful placement of Christophe Arbet-Engels , MD, PhD, as Chief Medical Officer (CMO) at X4 Pharmaceuticals, Inc. , a biopharmaceutical company developing novel small molecule therapeutics to benefit patients with diseases of the immune system.
  • Dr. Arbet-Engels is a highly respected and experienced global pharmaceutical executive with keen business acumen honed over more than 20 years serving in complex organizational settings," said Leslie Loveless, Slone Partners CEO.
  • "Dr. Arbet-Engels is a highly respected and experienced global pharmaceutical executive with keen business acumen honed over more than 20 years serving in complex organizational settings," said Leslie Loveless , Slone Partners CEO.
  • "It was truly a pleasure collaborating with Slone Partners on the placement of Christophe as our new Chief Medical Officer," said Paula Ragan , Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals, "We very much value our relationship with the Slone team and consider them a valuable ongoing resource to X4 given their deep understanding of and high quality connections within the life science industry."

X4 Pharmaceuticals Reports Second-Quarter 2023 Financial Results, Provides Corporate Updates, and Reports Emerging Data from Chronic Neutropenia Clinical Program

Retrieved on: 
Thursday, August 10, 2023

Additional data from this ongoing Phase 2 trial are expected to be shared in the fourth quarter of 2023.

Key Points: 
  • Additional data from this ongoing Phase 2 trial are expected to be shared in the fourth quarter of 2023.
  • X4 is planning to initiate a Phase 3 clinical trial evaluating mavorixafor in certain chronic neutropenic disorders in the first half of 2024.
  • X4 will host a conference call and webcast today at 8:30 am ET to discuss these financial results and business highlights.
  • The live webcast and slide presentation can be accessed on the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com .

EQS-News: Affluent Medical strengthens management team to advance its development

Retrieved on: 
Monday, July 17, 2023

Sébastien Ladet, CEO of Affluent Medical, commented: "I am delighted to welcome Christophe de Vregille and Benjamin Renault to the Affluent Medical management team at a time when we are approaching several decisive stages in the deployment of our development strategy.

Key Points: 
  • Sébastien Ladet, CEO of Affluent Medical, commented: "I am delighted to welcome Christophe de Vregille and Benjamin Renault to the Affluent Medical management team at a time when we are approaching several decisive stages in the deployment of our development strategy.
  • Benjamin brings a wealth of experience and knowledge in medical device development, which will be instrumental in preparing for commercialization and our expansion on international markets."
  • Benjamin Renault has over 15 years' experience in the development and international deployment of medical devices.
  • Overview of Affluent Medical’s management and leadership team:
    Christophe Giot, M.D., Chief Medical Officer and Vice President Clinical Affairs (Edwards, Terumo, Sanofi)
    Céline Buard, Marketing Director (Johnson & Johnson, BD, Eyetech Care)
    Eric Jague, Director of Regulatory Affairs (Medtronic, Fresenius Kabi)

Affluent Medical strengthens management team to advance its development.

Retrieved on: 
Monday, July 17, 2023

Affluent Medical strengthens management team to advance its development.

Key Points: 
  • Affluent Medical strengthens management team to advance its development.
  • Sébastien Ladet, CEO of Affluent Medical comments: "I am delighted to welcome Christophe de Vregille and Benjamin Renault to the Affluent Medical management team at a time when we are approaching several decisive stages in the deployment of our development strategy.
  • Benjamin Renault has over 15 years' experience in the development and international deployment of medical devices.
  • Overview of Affluent Medical’s management and leadership team:
    Christophe Giot, M.D., Chief Medical Officer and Vice President Clinical Affairs (Edwards, Terumo, Sanofi)
    Céline Buard, Marketing Director (Johnson & Johnson, BD, Eyetech Care)
    Eric Jague, Director of Regulatory Affairs (Medtronic, Fresenius Kabi)

American Express Announces Retirement of Chief Financial Officer Jeffrey C. Campbell and Names Deputy Chief Financial Officer Christophe Le Caillec as Successor

Retrieved on: 
Tuesday, June 27, 2023

American Express Company (NYSE:AXP) today announced that Jeffrey C. Campbell, Vice Chairman and Chief Financial Officer, has decided to retire from the company.

Key Points: 
  • American Express Company (NYSE:AXP) today announced that Jeffrey C. Campbell, Vice Chairman and Chief Financial Officer, has decided to retire from the company.
  • He will step down as the company’s CFO as of August 14, 2023, at which time Christophe Le Caillec, Deputy Chief Financial Officer, will succeed him as CFO, and join the American Express Executive Committee.
  • Prior to American Express, Mr. Campbell served as CFO of McKesson and American Airlines.
  • Le Caillec works closely with both Mr. Squeri and Mr. Campbell to drive the company’s financial success in executing the growth plan.

RGI Announces Appointment of Patricia Fouqueray as Country Manager of KAPIA-RGI

Retrieved on: 
Thursday, June 22, 2023

RGI Group, the European software solutions leader in insurance industry, announces the appointment of Patricia Fouqueray as new France Country Manager.

Key Points: 
  • RGI Group, the European software solutions leader in insurance industry, announces the appointment of Patricia Fouqueray as new France Country Manager.
  • Patricia Fouqueray succeeds Christophe Quesne, who will take on the role of Advisor of RGI Group.
  • Since 2018 Patricia has been the Managing Director of BlackRock Solutions for the Aladdin clients in France, Belgium, Luxembourg, Italy and Spain.
  • Patricia Fouqueray commented: “I am excited to join RGI Group and its highly experienced team to stretch and consolidate the growth on the French insurance industry.